NSC87877

Research use only, not for human use.

NSC-87877 is a cell-permeable inhibitor of both SHP-1 and SHP-2 with IC50 values of 355 and 318 nM respectively.

NSC-87877 is a cell-permeable inhibitor of both SHP-1 and SHP-2 with IC50 values of 355 and 318 nM respectively. It also inhibits EGF-induced Erk1/2 activation in HEK293 cells and significantly reduces MDA-MB-468 cell viability/proliferation.

NSC-87877 (0-0.5 μM, 5 days) inhibits DUSP26 function in NB cell lines.NSC-87877 (0-0.5 μM, 5 days) results in increased p53 phosphorylation (Ser37 and Ser46) and activation. Cell Viability Assay Cell Line:p53 wild-type neuroblastoma (NB) cell lines.Concentration:0, 0.25, 0.5 μM.Incubation Time:5 days.Result:Resulted in increased p53 phosphorylation (Ser37 and Ser46) and activation, increased activation of downstream p38 effector proteins (heat shock protein 27 (HSP27) and MAP kinase-activated protein kinase 2 (MAPKAPK2)) and poly ADP ribose polymerase/caspase-3 cleavage.Inhibited DUSP26 function in NB cell lines.Resulted in apoptosis in many cell lines at varying IC50 levels of 1.84 μM (IMR32), 6.35 μM (SK-N-SH), 8.69 μM (NB-19), 12.6 μM (SMS-KCN), 15.7 μM (SH-SY5Y), 15.8 μM (JF) and 19.0 μM (CHLA-225), respectively.

NSC-87877 (30?mg/kg, IP once daily for 15 days) possesses excellent anti- neuroblastoma activity. Animal Model:Intrarenal neuroblastoma (NB) tumor mouse model in female nude mice.Dosage:30 mg/kg. Administration:IP once daily for 15 days.Result:Significantly inhibited NB tumor growth.

——

Others

Other Targets

SHP-2|SHP-1

Neurological Disease

——

56932-43-5

503.42

C19H13N3O7S2·2Na

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (248.30 mM)

C1=CC2=C(C(=O)/C(=N/NC3=CC4=C(C=C3)C=C(C=C4)S(=O)(=O)[O-])/C=C2S(=O)(=O)[O-])N=C1.[Na+].[Na+]

——

(-20℃)

With Ice Pack

≥ 2 years